Brazil’s Opportunity in Advanced Therapy Medicinal Products

Brazil is often discussed as a future market for advanced therapies. That framing is too limited. Brazil should also be viewed as a potential development, manufacturing, clinical research, and access platform for advanced therapy medicinal products across Latin America.

The opportunity is real, but it is not automatic.

Advanced therapy medicinal products — including cell therapies, gene therapies, tissue-engineered products, and engineered immune-cell therapies — are not conventional drugs. They require specialized manufacturing, product-specific potency assays, rigorous traceability, long-term safety monitoring, and clinical evidence that is interpretable against a controlled product.

For Brazil, this creates both a challenge and an opening.

The challenge is that advanced therapies require capital, infrastructure, regulatory sophistication, clinical networks, trained personnel, and long-term quality systems. The opening is that Brazil already has several ingredients that many emerging markets lack: a large and structured healthcare system, high-level academic centers, clinical research capability, regulated biomanufacturing experience, and a national health authority with a dedicated framework for advanced therapy products.

Why Brazil matters for advanced therapies

Brazil combines four strategic characteristics.

First, Brazil has scale. The country has one of the world’s largest public healthcare systems and a large private healthcare sector. This creates both public-health relevance and a potential dual-channel access environment for advanced therapies.

Second, Brazil has clinical need. Oncology, hematology, autoimmune disease, cardiovascular disease, rare diseases, and degenerative conditions all create areas where advanced therapies may eventually play a role, provided that scientific rationale and clinical evidence are adequate.

Third, Brazil has scientific and clinical infrastructure. Major universities, cancer centers, public institutes, blood centers, hospitals, and private biotechnology groups can support translational development when aligned through proper governance.

Fourth, Brazil has regulatory structure. ANVISA has created a specific framework for Produtos de Terapia Avançada, including rules for registration, clinical research, and manufacturing expectations. This does not make development easy. It makes serious development possible.

The regulatory foundation: necessary, not sufficient

A defined regulatory pathway is a foundation. It is not a guarantee.

For advanced therapy medicinal products in Brazil, developers must consider the applicable ANVISA framework, including:

• RDC 505/2021, which addresses registration of advanced therapy products
• RDC 506/2021, which addresses clinical research with investigational advanced therapy products
• IN 270/2023, which addresses complementary good manufacturing practice requirements for advanced therapy products

The existence of these rules matters because serious investors, hospitals, clinical investigators, and international partners need regulatory predictability. But the rules also raise the bar. A product must be supported by CMC, quality, nonclinical rationale, clinical evidence, risk management, pharmacovigilance, and long-term follow-up where applicable.

For NK and CAR-NK platforms, this is especially important. A non-modified NK product and a CAR-NK product are not the same regulatory or CMC problem. CAR-NK introduces engineering, construct design, target selection, potency, comparability, biodistribution, persistence, and long-term follow-up questions that must be addressed product by product.

Brazil’s strategic window in cell therapy

The global cell therapy field is moving from proof of concept into industrialization. That transition creates a strategic window for countries that can combine scientific credibility with manufacturing discipline.

Brazil’s opportunity is not to copy the United States, Europe, China, or South Korea. Brazil’s opportunity is to build a differentiated LATAM model based on:

• Regulator-ready development
• Local GMP/BPF manufacturing
• Qualified clinical trial networks
• Ethical use of human biological materials
• Public and private healthcare integration
• Cost-aware product design
• International scientific partnerships
• Controlled technology transfer
• Evidence generation for local populations
• Protection of intellectual property and regulatory data

This is where BioNK’s strategic positioning becomes relevant. BioNK is focused on NK and CAR-NK advanced therapy platforms, including investigational programs that require controlled development before any clinical or commercial use. The platform opportunity depends not only on immunology, but on CMC, manufacturing, regulatory execution, clinical trial design, and access planning.

Why LATAM needs a regional advanced therapy platform

Latin America has substantial unmet medical need, but advanced therapies remain difficult to access. Barriers include cost, manufacturing complexity, limited specialized centers, regulatory heterogeneity, cold-chain logistics, reimbursement uncertainty, and dependence on imported products.

Brazil can address some of these barriers if it becomes a regional development and manufacturing platform.

A Brazil-based advanced therapy platform could support:

• Regional clinical trials
• Local manufacturing and release testing
• Reduced dependence on long-distance product logistics
• Training of specialized clinical centers
• Generation of LATAM-specific health-economic evidence
• Earlier interaction with regional regulators
• More realistic access models for public and private healthcare systems

However, this requires discipline. Regional ambition without GMP/BPF readiness, quality systems, regulatory clarity, and robust financing can increase risk rather than reduce it.

Public-health strategy: PDP, PDIL, and innovation policy

Brazil also has policy instruments that may support strategic health technologies, including public-private development mechanisms and innovation programs. PDP and PDIL structures can be relevant when the product fits public-health priorities and when technology transfer, local production, funding, and governance can be structured responsibly.

For advanced therapies, these mechanisms must be used cautiously. Cell therapy and gene-modified products are not ordinary pharmaceutical transfers. Technology transfer may involve sensitive know-how, proprietary cell-processing methods, analytical methods, potency assays, release criteria, cryopreservation systems, data rights, and regulatory documentation.

A responsible public-health strategy should protect:

• Patient safety
• Regulatory integrity
• BioNK and partner intellectual property
• Background IP
• Improvements
• Data ownership
• Pharmacovigilance obligations
• Manufacturing know-how
• Public-sector transparency
• Fair economic compensation
• Long-term sustainability

PDP and PDIL should not be presented as guaranteed pathways. They are possible instruments that require legal, regulatory, technical, economic, and governance validation.

What Brazil must get right

Brazil’s opportunity depends on execution. The country must avoid two opposite errors.

The first error is excessive dependency on imported products, where Brazil becomes only an end market for expensive therapies manufactured elsewhere.

The second error is premature localization, where complex technologies are transferred or announced before the manufacturing, quality, regulatory, and clinical evidence base is mature.

A credible path sits between these extremes. Brazil should focus on:

• Building specialized GMP/BPF cell therapy manufacturing capacity
• Training advanced therapy clinical sites
• Developing analytical and potency-assay competence
• Supporting translational clinical trials
• Structuring ethical access pathways
• Protecting intellectual property and regulatory data
• Using public policy instruments without weakening technical standards
• Aligning local development with FDA and EMA-compatible expectations where possible
• Creating evidence packages that can support Brazil first and LATAM later

The role of BioNK

BioNK’s role is not simply to promote a technology. Its role is to help build a disciplined advanced therapy platform around NK and CAR-NK science.

For BioNK, Brazil is strategically important because it can integrate:

• Biological starting material expertise
• Cell therapy manufacturing
• Cryopreservation and logistics
• Clinical research partnerships
• ANVISA regulatory development
• Public-health access planning
• International scientific collaboration
• LATAM expansion strategy

But this must remain phase-gated. Investigational products require clinical authorization before clinical use and regulatory approval before commercial use. Public-health access requires evidence, pricing, reimbursement, manufacturing capacity, and long-term monitoring. International partnerships require careful protection of IP, data, and manufacturing know-how.

What success would look like

Success would not be defined by a single announcement. It would be defined by a sequence of verifiable milestones:

• Clear target product profiles
• Complete CMC gap assessments
• Qualified manufacturing process
• Validated or justified release testing
• Potency assays linked to mechanism of action
• Regulatory interactions documented with ANVISA
• Ethically approved clinical trials
• Interpretable safety and efficacy datasets
• Pharmacovigilance and long-term follow-up plans
• Health-economic evidence relevant to Brazil
• Transparent and compliant public-private partnerships
• Protected IP and sustainable commercial terms

This is the standard required for Brazil to become a credible advanced therapy hub.

Bottom line

Brazil’s opportunity in advanced therapy medicinal products is real, but it is conditional.

The country has clinical need, scientific capacity, regulatory structure, manufacturing experience, and public-health relevance. But advanced therapies cannot be built on ambition alone. They require CMC discipline, GMP/BPF execution, ethical clinical research, regulatory maturity, long-term safety monitoring, IP protection, and sustainable access models.

For BioNK — and under the strategic perspective of Luís Eduardo da Cruz — Brazil is not only a market. It is a possible development platform for NK and CAR-NK advanced therapies in Latin America, including programs that may interface with strategic disease models like ovarian cancer. The opportunity is to build from Brazil with global compatibility.